Page 2 - Acorda News Today

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Esteve Pharmaceuticals GmbH has launched INBRIJA 33 mg (levodopa inhalation powder, hard capsules) in Germany. INBRIJA is indicated in the

Johnson afirma que volen garantir un pas segur de sortida Von der Leyen assenyala que el reconeixement del règim talibà no està sobre la taula

LAudiència de Girona acorda lexpulsió del país de lacusat quan accedeixi al tercer grau o a la llibertat condicional

Acorda: Q4 Earnings Snapshot FacebookTwitterEmail ARDSLEY, N.Y. (AP) _ Acorda Therapeutics Inc. (ACOR) on Thursday reported fourth-quarter profit of $83 million. On a per-share basis, the Ardsley, New York-based company said it had net income of $9.82. Losses, adjusted for non-recurring gains, came to $2.50 per share. The drugmaker posted revenue of $38.2 million in the period. For the year, the company reported that its loss narrowed to $99.6 million, or $12.32 per share. Revenue was reported ...

Acorda Rises On Restructuring, ALXN Pauses COVID-19 Trial, SYBX On Watch Read on. 1. Acorda Rises on Corporate Restructuring Shares of Acorda Therapeutics Inc. (ACOR) jumped over 44% on Wednesday, on news of the company agreeing to sell its INBRIJA manufacturing operations in Chelsea, Massachusetts to Catalent, Inc. (CTLT) for $80 million in cash. INBRIJA is a prescription medicine from Acorda Therapeutics indicated for use when needed with hypomobility or OFF episodes in adults with Parkinsons...

Item 8.01Other Events. On December 31, 2020, Acorda Therapeutics, Inc. filed a Certificate of Amendment to the Companys Amended and Restated Certificate of Incorporation with the Secretary of... | January 23, 2021